Britain takes leading role in drugs test

AIDS researchers hope a new approach to treating HIV-positive people using two or more drugs will prove more effective than treatment with AZT alone.

Many scientists believe that the HIV virus mutates so rapidly within the body that it soon develops strains resistant to AZT. Using two or more drugs, they say, makes this more difficult.

Britain will take a leading role in the drugs trial, called Delta, which it is hoped will discover the benefits - if any - of using AZT in conjunction with ddI, made by Bristol-Myers Squibb of the United States, and ddC, made by Roche of Switzerland. Both ddI and ddC work in a similar way to AZT by blocking a vital enzyme of HIV that it needs for replication.

Like the Anglo-French Concorde trial of AZT, the Delta investigation will be 'double- blind, placebo-controlled and randomised'. Neither doctor nor patient with know whether they are taking a placebo (dummy) pill or the real thing.

About 2,500 people will take part and the Medical Research Council hopes to have recruited the 700 British volunteers by the end of this month. It will be several years before the results emerge.

David Warrell, professor of tropical medicine and infectious diseases at Oxford University and head of an MRC committee on Aids, said two drugs working together may have a 'synergistic' effect, producing a greater benefit than each separately. He said there is much research on new anti-HIV drugs but the prospects are not promising.

Two alternatives to drugs are aimed at boosting the body's own defences against HIV before the virus can destroy the vital cells of the immune system.

Scientists from St Mary's Hospital and the Middlesex Hospital in London, working with the company British Biotechnology, have just begun the second phase of preliminary trials of a 'therapeutic vaccine' based on one of the proteins in the virus.

The aim is to encourage the immune system to recognise this viral protein and attack it, keeping virus replication in check. Researchers are testing the idea on 72 HIV-positive, healthy volunteers at clinics in London, Amsterdam and Antwerp.

Another approach, 'passive immunisation', is to take the natural antibodies produced by healthy HIV-positive people and infuse them into patients with Aids. Preliminary results have been promising, but Professor Warrell said: 'I have only seen preliminary data and although it's an interesting approach, I'm not convinced.'

Despite the 'enormous disappointment' of the AZT drugs trial, Professor Warrell said there is every hope that Aids may one day be treatable. 'I am reasonably confident because of the breadth and depth of the work. I don't believe it is an unconquerable virus.'

Suggested Topics
Start your day with The Independent, sign up for daily news emails
Have you tried new the Independent Digital Edition apps?
ebooksA celebration of British elections
Arts and Entertainment
Billie Piper as Brona in Penny Dreadful
tvReview: It’s business as usual in Victorian London. Let’s hope that changes as we get further into the new series spoiler alert
Life and Style
A nurse tends to a recovering patient on a general ward at The Queen Elizabeth Hospital in Birmingham
Arts and Entertainment
No Offence
tvReview: No Offence has characters who are larger than life and yet somehow completely true to life at the same time spoiler alert
Chuck Norris pictured in 1996
Arts and Entertainment
Sarah Lucas, I SCREAM DADDIO, Installation View, British Pavilion 2015
artWhy Sarah Lucas is the perfect choice to represent British art at the Venice Biennale
A voter placing a ballot paper in the box at a polling station
Arts and Entertainment
The Queen (Kristin Scott Thomas) in The Audience
theatreReview: Stephen Daldry's direction is crisp in perfectly-timed revival
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

SThree: Trainee Recruitment Consultant - Dublin

£13676.46 - £16411.61 per annum + OTE: SThree: SThree Trainee Recruitment Cons...

Ashdown Group: Marketing or Business Graduate Opportunity - Norwich - £22,000

£18000 - £22000 per annum + training: Ashdown Group: Business and Marketing Gr...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + Commission: SThree: Are you great at building rela...

Ashdown Group: Database Analyst - Birmingham - £22,000 plus benefits

£20000 - £22000 per annum + excellent benefits: Ashdown Group: Application Sup...

Day In a Page

General Election 2015: Ed Miliband's unlikely journey from hapless geek to heart-throb

Miliband's unlikely journey from hapless geek to heart-throb

He was meant to be Labour's biggest handicap - but has become almost an asset
General Election 2015: A guide to the smaller parties, from the the National Health Action Party to the Church of the Militant Elvis Party

On the margins

From Militant Elvis to Women's Equality: a guide to the underdogs standing in the election
Amr Darrag: Ex-Muslim Brotherhood minister in exile still believes Egypt's military regime can be replaced with 'moderate' Islamic rule

'This is the battle of young Egypt for the future of our country'

Ex-Muslim Brotherhood minister Amr Darrag still believes the opposition can rid Egypt of its military regime and replace it with 'moderate' Islamic rule, he tells Robert Fisk
Why patients must rely less on doctors: Improving our own health is the 'blockbuster drug of the century'

Why patients must rely less on doctors

Improving our own health is the 'blockbuster drug of the century'
Sarah Lucas is the perfect artist to represent Britain at the Venice Biennale

Flesh in Venice

Sarah Lucas has filled the British pavilion at the Venice Biennale with slinky cats and casts of her female friends' private parts. It makes you proud to be a woman, says Karen Wright
11 best anti-ageing day creams

11 best anti-ageing day creams

Slow down the ageing process with one of these high-performance, hardworking anti-agers
Juventus 2 Real Madrid 1: Five things we learnt, including Iker Casillas is past it and Carlos Tevez remains effective

Juventus vs Real Madrid

Five things we learnt from the Italian's Champions League first leg win over the Spanish giants
Ashes 2015: Test series looks a lost cause for England... whoever takes over as ECB director of cricket

Ashes series looks a lost cause for England...

Whoever takes over as ECB director of cricket, says Stephen Brenkley
Fishing for votes with Nigel Farage: The Ukip leader shows how he can work an audience as he casts his line to the disaffected of Grimsby

Fishing is on Nigel Farage's mind

Ukip leader casts a line to the disaffected
Who is bombing whom in the Middle East? It's amazing they don't all hit each other

Who is bombing whom in the Middle East?

Robert Fisk untangles the countries and factions
China's influence on fashion: At the top of the game both creatively and commercially

China's influence on fashion

At the top of the game both creatively and commercially
Lord O’Donnell: Former cabinet secretary on the election and life away from the levers of power

The man known as GOD has a reputation for getting the job done

Lord O'Donnell's three principles of rule
Rainbow shades: It's all bright on the night

Rainbow shades

It's all bright on the night
'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

Bread from heaven

Dutch survivors thank RAF for World War II drop that saved millions
Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

How 'the Axe' helped Labour

UK will be 'run for the wealthy and powerful' if Tories retain power